Jefferies is out with an analyst note this morning, where they reiterated their Hold rating on shares of Vivus Inc. (NASDAQ: VVUS); they have a $9.00 price target on the stock. Jefferies analysts said that they “have greater comfort with the ...
Starts next phase of key obesity study next year (Adds head of global research, background, graphic) By Stine …
MOUNTAIN VIEW, Calif. and NEW YORK, July 18, 2013 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS) ("VIVUS" or "the Company"), a pharmaceutical company commercializing and developing innovative, next-generation therapies to …
Vivus’s Qnexa, the first of three new anti-obesity drugs under FDA review this year, came before one of the agency’s advisory committees today — and it was a swing and a miss. The panel recommended against …
VIVUS, Inc. (NASDAQ:VVUS) shares soared 11% to $20.58 after Bloomberg Industries claims the prescription insurer …